Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Open accessAbstract
IMPORTANCE: Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies. OBJECTIVE: To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI). DATA SOURCES: Relevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators. STUDY SELECTION: Studies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity. DATA EXTRACTION AND SYNTHESIS: Individual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies. MAIN OUTCOMES AND MEASURES: Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations. RESULTS: The prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality. CONCLUSIONS AND RELEVANCE: Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Case-control studies without neuropathological or biomarker assessments of AD may have underestimated the impact of APOE genotypes on Alzheimer's dementia odds ratios due to the confounding effects of APOE genotypes on the percentages of neuropathologically misclassified cases and controls.
“This possibility has remained unaddressed, because case–control studies without neuropathological or biomarker assessments of AD may have underestimated the impact of APOE genotypes on Alzheimer’s dementia ORs due to the confounding effects of APOE genotypes on the percentages of neuropathologically misclassified cases and controls8–10.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [10]
Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredDue to prioritized ascertainment, the number of misclassified cases and controls available through the AD Genetics Consortium is much smaller than the estimated number of neuropathologically misclassified cases and controls, limiting the ability to clarify the impact of brain donation on APOE ORs in post hoc analyses.
“Due to the prioritized ascertainment of those cases who met the clinical and neuropathological criteria for Alzheimer’s dementia and those unimpaired controls without AD, the number of misclassified cases and controls available through the AD Genetics Consortium12 is much smaller than our estimated number of neuropathologically misclassified cases and controls8–11, limiting our ability to clarify”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [10]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredUp to 60% of CU individuals over age 80 years have AD neuropathologic changes at autopsy or by biomarkers.
“Up to 60% of CU individuals over age 80 years have AD neuropathologic changes at autopsy or by biomarkers [60,152,212–214].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [60]
The paper reports amyloid pathology in cognitively normal people and cites neuropathological studies finding 10%–60% prevalence in people without dementia (Introduction; page not provided). But that 60% range is not specific to people over 80. Its own biomarker results estimate 44% at age 90 overall, while the Discussion reports more than 80% among APOE-ε4 carriers with normal cognition, so the stated age-specific upper figure is not established by this source. (LLM, conf=0.85)
Experimental — accuracy not yet measuredThere is a suggested 2- to 30-year interval between first development of Aβ positivity and onset of dementia.
“In epidemiological cohorts assessing patients without dementia using amyloid PET status or CSF profile, Aβ pathology was associated with APOE genotype, presence of cognitive impairment and suggested a 2- to 30- year interval between first development of Αβ positivity and onset of dementia [3, 169].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [169]
The Conclusions and Discussion suggest a 20- to 30-year interval between first amyloid positivity and dementia, not the claimed 2- to 30-year interval. The source supports the suggested interval but not its 2-year lower bound. (LLM, conf=0.90)
Experimental — accuracy not yet measuredThe association of the APOE4 isoform with amyloid deposition has been well established in human studies, where APOE4 carriers exhibit higher Aβ plaque burden and earlier onset of amyloid positivity compared with non-carriers.
“The association of the APOE4 isoform with amyloid deposition has been well established in human studies, where APOE4 carriers exhibit higher A β plaque burden and earlier onset of amyloid positivity compared with non-carriers 35 -37 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [35]
The Results (Prevalence of Amyloid Positivity; page not provided) report higher amyloid-positivity prevalence in APOE-ε4 carriers and an earlier age at which carriers reach 15% positivity. The paper does not establish that carriers have a higher Aβ plaque burden per person; it reports the prevalence of biomarker-defined amyloid pathology instead. (LLM, conf=0.88)
Experimental — accuracy not yet measured
People with the APOE-e4 form are more likely to have beta-amyloid accumulation and Alzheimer's dementia at a younger age than those with the e2 or e3 forms.
“In addition, those with the e4 form are more likely to have beta-amyloid accumulation and Alzheimer's dementia at a younger age than those with the e2 or e3 forms of the APOE gene.76,77”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [76]
A meta-analysis reported a prevalence of amyloid pathology among individuals with SCD of 12%-43%.
“A meta-analysis reported a prevalence of amyloid pathology among individuals with SCD of 12%-43% [22].”
From Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease (2020) · cites this paper as [22]
Prevalence of Aβ+ is substantially higher in APOE ε4 carriers.
“Owing to the substantially higher prevalence of Aβ+ in APOE ε4 carriers18,19,28, plasma biomarkers had higher PPVs for brain amyloid-β, particularly in individuals with MCI.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [28]
A similar proportion of cognitively unimpaired elderly persons has abnormal amyloid biomarkers.
“and a similar proportion has abnormal amyloid biomarkers [33,53–55,60,70–73].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [60]
In epidemiological cohorts of patients without dementia, Aβ pathology was associated with APOE genotype and presence of cognitive impairment.
“In epidemiological cohorts assessing patients without dementia using amyloid PET status or CSF profile, Aβ pathology was associated with APOE genotype, presence of cognitive impairment and suggested a 2- to 30- year interval between first development of Αβ positivity and onset of dementia [3, 169].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [169]
In a previous autopsy study, 25% of persons with the clinical diagnosis of mild-to-moderate Alzheimer's dementia lacked at least moderately frequent neuritic plaques, including 37% of APOE4 non-carriers and 13% of carriers.
“In a previous autopsy study, we found that 25% of persons with the clinical diagnosis of mild-to-moderate Alzheimer’s dementia lacked at least moderately frequent neuritic plaques, one of the cardinal features of AD, including 37% of APOE4 non-carriers and 13% of carriers, findings that are consistent with those in living patients9,10.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [10]
The Results (Participant Characteristics) describe living participants with normal cognition, subjective cognitive impairment, or mild cognitive impairment, not an autopsy cohort with diagnosed Alzheimer’s dementia. The Results (Prevalence of Amyloid Positivity) report APOE-related differences in biomarker positivity, but our copy does not report the claimed absence of neuritic plaques or the 25%, 37%, and 13% autopsy figures. (LLM, conf=0.78)
Experimental — accuracy not yet measuredA similar proportion of individuals clinically diagnosed as AD dementia have normal amyloid PET or CSF Aβ42 studies.
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [60]
The Methods state that the included biomarker studies enrolled participants without dementia, and the Results describe participants with normal cognition, subjective cognitive impairment, or mild cognitive impairment. I searched for normal amyloid PET or CSF Aβ42 results in clinically diagnosed AD dementia, but found no passage reporting that proportion. (LLM, conf=0.78)
Experimental — accuracy not yet measuredAβ load correlates better with age than disease severity in AD.
“the Aβ load, which has been our main target, correlates better with age than disease severity in AD [291,292,293]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [293]
Substantial amyloid pathology is already present in the neocortex decades before overt Alzheimer disease symptoms appear.
“Substantial amyloid pathology is already present in the neocortex decades prior to overt AD symptomatology”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [17]
The trigger scenario can be discounted because amyloid deposition may begin about 20 years before cognitive changes.
“The trigger scenario can be discounted as the onset of amyloid deposition may occur ~20 years prior to cognitive alterations”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [17]
Between the appearance of amyloid plaques and neuronal tangles in the human brain, to the ultimate dementia in patients, up to twenty years may elapse.
“Between the appearance of amyloid plaques and neuronal tangles in the human brain, to the ultimate dementia in patients, up to twenty years may elapse (Bateman et al. , 2012; Villemagne et al. , 2013; Jansen et al. , 2015).”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Jansen et al., 2015
Studies estimating Alzheimer's disease duration should be age-specific and should account for APOE genotype, sex, and cerebrospinal fluid tau levels.
“Attempts to quantify the duration of AD should be age-specific, because age imposes the greatest risk for both dementia and mortality, and take into account APOE genotype, sex, and cerebrospinal fluid (CSF) tau levels [4, 6, 10-12].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype (2019) · cites this paper as [4]
Amyloid accumulation in the brain is thought to be the earliest sign of Alzheimer's disease and may begin up to 20 years before a clinical dementia diagnosis.
“Accumulation of amyloid in the brain is believed to be the first sign of the disease and can precede a clinical diagnosis of dementia by up to 20 years [1, 4, 5].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype (2019) · cites this paper as [4]
Among individuals who were cognitively unimpaired on objective cognitive testing, there was no difference in frequency of CSF Alzheimer's disease profiles between people with and people without subjective cognitive decline.
“Among individuals who were cognitively unimpaired on objective cognitive testing, there was no difference in frequency of CSF Alzheimer’s disease profiles between people with and people without subjective cognitive decline.83”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works
Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., Egger, M., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040297 · Cited by 8,613 · see citing works
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864 · see citing works
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works
Self-citationWinblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946 · see citing works
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · see citing works
Self-citationWhiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592 · see citing works
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · see citing works
Self-citationVandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., & Egger, M. (2007) · Epidemiology · doi:10.1097/ede.0b013e3181577511 · Cited by 2,779 · see citing works
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279 · see citing works
Self-citationDementia: a public health priority
Acosta, D. M., Krishnamoorthy, E. S., Wortmann, M., Prince, M. J., & Saxena, S. (2012) · Cited by 1,955 · see citing works
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · see citing works
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · see citing works
Self-citationBiomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002 · see citing works
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · see citing works
Self-citationAge, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900 · see citing works
Cognitive Reserve and Alzheimer Disease
Stern, Y. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213815.20177.19 · Cited by 838 · see citing works
<i>APOE</i> predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830 · see citing works
Self-citationAPOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714 · see citing works
Self-citationSex Differences in the Clinical Manifestations of Alzheimer Disease Pathology
Barnes, L. L., Wilson, R. S., Bienias, J. L., Schneider, J. A., Evans, D. A., & Bennett, D. A. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.685 · Cited by 643 · see citing works
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · see citing works
Self-citationTesting the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550 · see citing works
Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions
Bennett, D. A., Schneider, J. A., Bienias, J. L., Evans, D. A., & Wilson, R. S. (2005) · Neurology · doi:10.1212/01.wnl.0000152982.47274.9e · Cited by 537 · see citing works
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals
Amariglio, R. E., Becker, J. A., Carmasin, J., Wadsworth, L. P., Lorius, N., Sullivan, C., Maye, J. E., Gidicsin, C., Pepin, L. C., Sperling, R. A., et al. (2012) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2012.08.011 · Cited by 472 · see citing works
Evans, D. A., Hebert, L. E., Beckett, L. A., Scherr, P. A., Albert, M. S., Chown, M. J., Pilgrim, D. M., & Taylor, J. O. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550230066019 · Cited by 435 · see citing works
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434 · see citing works
Self-citationComparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid
Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23908 · Cited by 401 · see citing works
Self-citationCSF biomarker variability in the Alzheimer's Association quality control program
Mattsson, N., Andréasson, U., Persson, S., Carrillo, M. C., Collins, S. J., Chalbot, S., Cutler, N. E., Dufour‐Rainfray, D., Fagan, A. M., Heegaard, N. H. H., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.010 · Cited by 383 · see citing works
Self-citationAge, Sex, andAPOEε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Vemuri, P., Mielke, M. M., Lowe, V. J., Senjem, M. L., Gunter, J. L., Machulda, M. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4821 · Cited by 382 · see citing works
Relationship between atrophy and β‐amyloid deposition in Alzheimer disease
Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373 · see citing works
Self-citationPalmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368 · see citing works
Self-citationJack, C. R., Wiste, H. J., Weigand, S. D., Rocca, W. A., Knopman, D. S., Mielke, M. M., Lowe, V. J., Senjem, M. L., Gunter, J. L., Preboske, G. M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70194-2 · Cited by 358 · see citing works
Meta-analysis of amyloid-cognition relations in cognitively normal older adults
Hedden, T., Oh, H., Younger, A. P., & Patel, T. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828ab35d · Cited by 320 · see citing works
Cognitive Reserve and Alzheimer’s Disease
Xu, W., Yu, J., Tan, M., & Tan, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8720-y · Cited by 240 · see citing works
Individual Participant Data Meta-Analysis for a Binary Outcome: One-Stage or Two-Stage?
Debray, T. P. A., Moons, K. G. M., Abo-Zaid, G., Koffijberg, H., & Riley, R. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060650 · Cited by 201 · see citing works
van Harten, A. C., Visser, P. J., Pijnenburg, Y. A. L., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.08.004 · Cited by 197 · see citing works
Self-citationSuri, S., Heise, V., Trachtenberg, A. J., & Mackay, C. E. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.010 · Cited by 183 · see citing works
Schöll, M., Wall, A., Thordardottir, S., Ferreira, D., Bogdanovic, N., Långström, B., Almkvist, O., Graff, C., & Nordberg, A. (2012) · Neurology · doi:10.1212/wnl.0b013e31825fdf18 · Cited by 169 · see citing works
Self-citationAmyloid imaging as a biomarker for cerebral β-amyloidosis and risk-prediction for Alzheimer dementia
Klunk, W. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.006 · Cited by 134 · see citing works
Self-citationMatthews, F. E., & Brayne, C. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020193 · Cited by 134 · see citing works
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene
Boehm-Cagan, A., & Michaelson, D. M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5198-13.2014 · Cited by 134 · see citing works
Liao, F., Hori, Y., Hudry, E., Bauer, A. Q., Jiang, H., Mahan, T. E., Lefton, K. B., Zhang, T. J., Dearborn, J. T., Kim, J., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0646-14.2014 · Cited by 128 · see citing works
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124 · see citing works
Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort
Zwan, M. D., van Harten, A. C., Ossenkoppele, R., Bouwman, F. H., Teunissen, C. E., Adriaanse, S. F., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. M., & van der Flier, W. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132561 · Cited by 120 · see citing works
Self-citationSystematic review of methods for individual patient data meta- analysis with binary outcomes
Thomas, D., Radji, S., & Benedetti, A. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-79 · Cited by 110 · see citing works
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Frosch, M. P., Betensky, R. A., & Hyman, B. T. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000016 · Cited by 105 · see citing works
Neuropathological diagnostic criteria for Alzheimer's disease
Murayama, S., & Saito, Y. (2004) · Neuropathology · doi:10.1111/j.1440-1789.2004.00571.x · Cited by 92 · see citing works
Brodaty, H., Mothakunnel, A., de Vel‐Palumbo, M., Ames, D. J., Ellis, K. A., Reppermund, S., Kochan, N. A., Savage, G. R., Trollor, J. N., Crawford, J., et al. (2013) · Annals of Epidemiology · doi:10.1016/j.annepidem.2013.10.005 · Cited by 79 · see citing works
Alzheimer disease identification using amyloid imaging and reserve variables
Roe, C. M., Mintun, M. A., Ghoshal, N., Williams, M., Grant, E., Marcus, D. S., & Morris, J. C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e620f4 · Cited by 45 · see citing works
Self-citationLin, Y.-T., Cheng, J., Yao, Y.-C., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1214 · Cited by 31 · see citing works
Cerebrospinal fluid biomarkers of Alzheimer’s disease in cognitively healthy elderly
Glodzik, L. (2013) · Frontiers in bioscience · doi:10.2741/4170 · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works
Self-citation2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212 · see citing works
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125 · see citing works
Self-citation2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353 · see citing works
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · see citing works
Self-citationThe Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952 · see citing works
Self-citationPreclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · see citing works
Self-citationMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853 · see citing works
Self-citationDefeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676 · see citing works
Self-citationApolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · see citing works
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242 · see citing works
Biomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159 · see citing works
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051 · see citing works
“In this regard, it is noteworthy that the frequency of CSF AD profiles between those with normal cognition and SMC is similar 58 .”
ResultSelf-citationAPOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037 · see citing works
Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease
Chen, W.-T., Lu, A., Craessaerts, K., Pavie, B., Sala Frigerio, C., Corthout, N., Qian, X., Laláková, J., Kühnemund, M., Voytyuk, I., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.038 · Cited by 949 · see citing works
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931 · see citing works
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965 · see citing works
Global estimates on the number of persons across the Alzheimer's disease continuum
Gustavsson, A., Norton, N., Fast, T., Frölich, L., Georges, J., Holzapfel, D., Kirabali, T., Krolak‐Salmon, P., Rossini, P. M., Ferretti, M. T., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12694 · Cited by 895 · see citing works
Mitochondria and Mitochondrial Cascades in Alzheimer’s disease
Swerdlow, R. H. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170585 · Cited by 850 · see citing works
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742 · see citing works
Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis
Ossenkoppele, R., Jansen, W. J., Rabinovici, G. D., Knol, D. L., van der Flier, W. M., van Berckel, B. N. M., Scheltens, P., Visser, P. J., Verfaillie, S. C. J., Zwan, M. D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4669 · Cited by 677 · see citing works
Self-citationRabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., Hendrix, J., Hillner, B. E., Olson, C., Lesman-Segev, O. H., et al. (2019) · JAMA · doi:10.1001/jama.2019.2000 · Cited by 674 · see citing works
Self-citationAssociation Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition
Gottesman, R. F., Schneider, A. L. C., Zhou, Y., Coresh, J., Green, E., Gupta, N., Knopman, D. S., Mintz, A., Rahmim, A., Sharrett, A. R., et al. (2017) · JAMA · doi:10.1001/jama.2017.3090 · Cited by 650 · see citing works
Imaging the evolution and pathophysiology of Alzheimer disease
Jagust, W. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0067-3 · Cited by 604 · see citing works
Self-citationHansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607 · see citing works
Self-citationVermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P., Maruff, P., Skoog, I., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.04.001 · Cited by 570 · see citing works
Self-citationEpileptic activity in Alzheimer’s disease: Causes and clinical relevance
Vossel, K. A., Tartaglia, M. C., Nygaard, H. B., Zeman, A. Z., & Miller, B. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30044-3 · Cited by 590 · see citing works
Amyloid-β-independent regulators of tau pathology in Alzheimer disease
van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0240-3 · Cited by 580 · see citing works
Self-citationPalmqvist, S., Tideman, P., Cullen, N., Zetterberg, H., Blennow, K., Initiative, T. A. D. N., Dage, J. L., Stomrud, E., Janelidze, S., Mattsson-Carlgren, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01348-z · Cited by 524 · see citing works
Self-citationChételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526 · see citing works
Self-citationReiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14279-8 · Cited by 473 · see citing works
Self-citationApoE4 Accelerates Early Seeding of Amyloid Pathology
Liu, C.-C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C.-W., & Bu, G. (2017) · Neuron · doi:10.1016/j.neuron.2017.11.013 · Cited by 451 · see citing works
Ossenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.12917 · Cited by 472 · see citing works
Self-citationCircadian rest-activity pattern changes in aging and preclinical Alzheimer disease
Musiek, E. S., Bhimasani, M., Zangrilli, M. A., Morris, J. C., Holtzman, D. M., & Ju, Y.-E. S. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4719 · Cited by 465 · see citing works
Self-citationAgeing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448 · see citing works
Body mass index and risk of dementia: analysis of individual-level data from 1·3 million individuals
Kivimäki, M., Luukkonen, R., Batty, G. D., Ferrie, J. E., Pentti, J., Nyberg, S. T., Shipley, M. J., Alfredsson, L., Fransson, E. I., Goldberg, M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.016 · Cited by 440 · see citing works
Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435 · see citing works
Self-citationBiomarker Changes during 20 Years Preceding Alzheimer’s Disease
Jia, J., Ning, Y., Chen, M., Wang, S., Yang, H., Li, F., Ding, J., Li, Y., Zhao, B., Lyu, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2310168 · Cited by 455 · see citing works
Trial of solanezumab in preclinical Alzheimer's disease
Sperling, R. A., Donohue, M. C., Raman, R., Rafii, M. S., Johnson, K., Masters, C. L., van Dyck, C. H., Iwatsubo, T., Marshall, G. A., Yaari, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2305032 · Cited by 429 · see citing works
Emerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381 · see citing works
Impairments of neural circuit function in Alzheimer's disease
Busche, M. A., & Konnerth, A. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0429 · Cited by 360 · see citing works
APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease
Fortea, J., Pegueroles, J., Alcolea, D., Belbin, O., Dols-Icardo, O., Vaqué-Alcázar, L., Videla, L., Gispert, J. D., Suárez-Calvet, M., Johnson, S. C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02931-w · Cited by 369 · see citing works
Self-citationAlzheimer's disease: From immunotherapy to immunoprevention
Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353 · see citing works
Ossenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1858 · Cited by 311 · see citing works
Self-citationCan physical exercise in old age improve memory and hippocampal function?
Duzel, E., van Praag, H., & Sendtner, M. (2016) · Brain · doi:10.1093/brain/awv407 · Cited by 329 · see citing works
Alzheimer’s disease drug development pipeline: 2024
Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2024) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12465 · Cited by 702 · see citing works
Jack, C. R., Therneau, T. M., Weigand, S. D., Wiste, H. J., Knopman, D. S., Vemuri, P., Lowe, V. J., Mielke, M. M., Roberts, R. O., Machulda, M. M., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1971 · Cited by 300 · see citing works
Depression—an underrecognized target for prevention of dementia in Alzheimer’s disease
Dafsari, F. S., & Jessen, F. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0839-1 · Cited by 312 · see citing works
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., Amyloid Biomarker Study Group, Aarsland, D., Alcolea, D., Altomare, D., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5216 · Cited by 290 · see citing works
Self-citationNeuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease
Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00395-3 · Cited by 265 · see citing works
Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia
Ismail, Z., Black, S. E., Camicioli, R., Chertkow, H., Herrmann, N., Laforce, R., Montero‐Odasso, M., Rockwood, K., Rosa‐Neto, P., Seitz, D., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12105 · Cited by 245 · see citing works
Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia
van der Flier, W. M., de Vugt, M. E., Smets, E. M. A., Blom, M., & Teunissen, C. E. (2023) · Nature Aging · doi:10.1038/s43587-023-00404-2 · Cited by 220 · see citing works
Self-citationRoberts, R. O., Aakre, J. A., Kremers, W. K., Vassilaki, M., Knopman, D. S., Mielke, M. M., Alhurani, R., Geda, Y. E., Machulda, M. M., Coloma, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0629 · Cited by 223 · see citing works
Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
Kim, C. K., Lee, Y. R., Ong, L., Gold, M., Kalali, A., & Sarkar, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215699 · Cited by 241 · see citing works
Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
Sinsky, J., Pichlerova, K., & Hanes, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179207 · Cited by 220 · see citing works
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212 · see citing works
Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia
Bergeron, D., Gorno‐Tempini, M. L., Rabinovici, G. D., Santos‐Santos, M. A., Seeley, W., Miller, B. L., Pijnenburg, Y., Keulen, M. A., Groot, C., van Berckel, B. N. M., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25333 · Cited by 203 · see citing works
Self-citationAmyloid blood biomarker detects Alzheimer's disease
Nabers, A., Perna, L., Lange, J., Mons, U., Schartner, J., Güldenhaupt, J., Saum, K., Janelidze, S., Holleczek, B., Rujescu, D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708763 · Cited by 185 · see citing works
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 186 · see citing works
“In epidemiological cohorts assessing patients without dementia using amyloid PET status or CSF pro fi le, A β pathology was associated with APOE genotype, presence of cognitive impairment and suggested a 2-to 30-year interval between fi rst development of Αβ positivity and onset of dementia [3, 169].”
BackgroundDuara, R., & Barker, W. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01185-z · Cited by 187 · see citing works
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
Öhrfelt, A., Brinkmalm, A., Dumurgier, J., Brinkmalm, G., Hansson, O., Zetterberg, H., Bouaziz-Amar, E., Hugon, J., Paquet, C., & Blennow, K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0208-8 · Cited by 184 · see citing works
Self-citationDistinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease
Schöll, M., Ossenkoppele, R., Strandberg, O., Palmqvist, S., study, T. S. B., Jögi, J., Ohlsson, T., Smith, R., & Hansson, O. (2017) · Brain · doi:10.1093/brain/awx171 · Cited by 180 · see citing works
Self-citationAmyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019) · Annals of Neurology · doi:10.1002/ana.25410 · Cited by 178 · see citing works
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809316 · Cited by 177 · see citing works
Brookmeyer, R., & Abdalla, N. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.005 · Cited by 176 · see citing works
A second X chromosome contributes to resilience in a mouse model of Alzheimer’s disease
Davis, E. J., Broestl, L., Abdulai-Saiku, S., Worden, K., Bonham, L. W., Miñones-Moyano, E., Moreno, A. J., Wang, D., Chang, K., Williams, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5677 · Cited by 176 · see citing works
Circadian disruption and sleep disorders in neurodegeneration
Shen, Y., Lv, Q.-K., Xie, W.-Y., Gong, S.-Y., Zhuang, S., Liu, J.-Y., Mao, C.-J., & Liu, C.-F. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00340-6 · Cited by 171 · see citing works
Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease
Iaccarino, L., Tammewar, G., Ayakta, N., Baker, S. L., Bejanin, A., Boxer, A. L., Gorno-Tempini, M. L., Janabi, M., Kramer, J. H., Lazaris, A., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.09.016 · Cited by 165 · see citing works
Self-citationOssenkoppele, R., Lyoo, C. H., Jester-Broms, J., Sudre, C. H., Cho, H., Ryu, Y. H., Choi, J. Y., Smith, R., Strandberg, O., Palmqvist, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.5154 · Cited by 161 · see citing works
Herbert, J., & Lucassen, P. J. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2015.12.001 · Cited by 150 · see citing works
Markers of neuroinflammation associated with Alzheimer’s disease pathology in older adults
Popp, J., Oikonomidi, A., Tautvydaitė, D., Dayon, L., Bacher, M., Migliavacca, E., Henry, H., Kirkland, R., Severin, I., Wojcik, J., et al. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.01.020 · Cited by 136 · see citing works
Self-citationMahan, T. E., Wang, C., Bao, X., Choudhury, A., Ulrich, J. D., & Holtzman, D. M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00516-0 · Cited by 134 · see citing works
Huynh, T.-P. V., Wang, C., Tran, A. C., Tabor, G. T., Mahan, T. E., Francis, C. M., Finn, M. B., Spellman, R., Manis, M., Tanzi, R. E., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0337-1 · Cited by 139 · see citing works
Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies
Su, Y., Flores, S., Hornbeck, R. C., Speidel, B., Vlassenko, A. G., Gordon, B. A., Koeppe, R. A., Klunk, W. E., Xiong, C., Morris, J. C., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.04.022 · Cited by 126 · see citing works
Self-citationDESGESCO (Dementia Genetics Spanish Consortium), E. (. D. E. D. B., van der Lee, S. J., biobank), E. (. D. E. D., IFGC (International FTD-Genomics Consortium), I. (. I. P. D. G. C., IPDGC (The International Parkinson Disease Genomics Consortium), Dementia), R.-F. (. A. M. F. I. F.-T., (NBB), N. B. B., The GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Conway, O. J., Jansen, I., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02026-8 · Cited by 120 · see citing works
Self-citationThe implications of different approaches to define AT(N) in Alzheimer disease
Mattsson-Carlgren, N., Leuzy, A., Janelidze, S., Palmqvist, S., Stomrud, E., Strandberg, O., Smith, R., & Hansson, O. (2020) · Neurology · doi:10.1212/wnl.0000000000009485 · Cited by 114 · see citing works
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129 · see citing works
Jack, C. R., Therneau, T. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Mielke, M. M., Vemuri, P., Roberts, R. O., Machulda, M. M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00323-3 · Cited by 129 · see citing works
Cacciaglia, R., Molinuevo, J. L., Falcón, C., Brugulat‐Serrat, A., Sánchez‐Benavides, G., Gramunt, N., Esteller, M., Morán, S., Minguillón, C., Fauria, K., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.016 · Cited by 124 · see citing works
Self-citationPredicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117 · see citing works
Tong, B., Ba, Y., Li, Z., Yang, C., Su, K., Qi, H., Zhang, D., Liu, X., Wu, Y., Chen, Y., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106505 · Cited by 117 · see citing works
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116 · see citing works
Wolfsgruber, S., Polcher, A., Koppara, A., Kleineidam, L., Frölich, L., Peters, O., Hüll, M., Rüther, E., Wiltfang, J., Maier, W., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161252 · Cited by 114 · see citing works
Self-citationDiagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability
Therriault, J., Janelidze, S., Benedet, A. L., Ashton, N. J., Arranz Martínez, J., Gonzalez-Escalante, A., Bellaver, B., Alcolea, D., Vrillon, A., Karim, H., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00731-y · Cited by 112 · see citing works
“The results of our study used amyloid-β pathology prevalence estimates derived from the Amyloid Biomarker Study Group, an international multicenter study of more than 19,000 individuals 19,28 .”
InfluentialSelf-citationPET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102 · see citing works
Tian, D.-Y., Cheng, Y., Zhuang, Z.-Q., He, C.-Y., Pan, Q.-G., Tang, M.-Z., Hu, X.-L., Shen, Y.-Y., Wang, Y.-R., Chen, S.-H., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01073-6 · Cited by 100 · see citing works
Staffaroni, A., Elahi, F., McDermott, D., Marton, K., Karageorgiou, E., Sacco, S., Paoletti, M., Caverzasi, E., Hess, C., Rosen, H., et al. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1608808 · Cited by 91 · see citing works
BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Sardone, R., Piccininni, C., Dibello, V., Stallone, R., Giannelli, G., Bellomo, A., Greco, A., et al. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1531706 · Cited by 92 · see citing works
Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Bertens, D., Tijms, B. M., Scheltens, P., Teunissen, C. E., & Visser, P. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0233-7 · Cited by 91 · see citing works
Self-citationMattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.009 · Cited by 88 · see citing works
Self-citationMRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study
ten Kate, M., Redolfi, A., Peira, E., Bos, I., Vos, S. J., Vandenberghe, R., Gabel, S., Schaeverbeke, J., Scheltens, P., Blin, O., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0428-1 · Cited by 78 · see citing works
Self-citationHampel, H., Shaw, L. M., Aisen, P., Chen, C., Lleó, A., Iwatsubo, T., Iwata, A., Yamada, M., Ikeuchi, T., Jia, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12372 · Cited by 77 · see citing works
Self-citationBiomarkers for Alzheimer’s Disease
Guzman-Martinez, L., Maccioni, R. B., Farías, G. A., Fuentes, P., & Navarrete, L. P. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190517121140 · Cited by 87 · see citing works
Chételat, G., Ossenkoppele, R., Villemagne, V. L., Perrotin, A., Landeau, B., Mézenge, F., Jagust, W. J., Dore, V., Miller, B. L., Egret, S., et al. (2016) · Brain · doi:10.1093/brain/aww159 · Cited by 80 · see citing works
Self-citationA 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes
Lleó, A., Irwin, D. J., Illán-Gala, I., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0118 · Cited by 71 · see citing works
Self-citationPeet, B. T., Spina, S., Mundada, N., & La Joie, R. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01101-x · Cited by 74 · see citing works
APOE effects on regional tau in preclinical Alzheimer’s disease
Young, C. B., Johns, E., Kennedy, G., Belloy, M. E., Insel, P. S., Greicius, M. D., Sperling, R. A., Johnson, K. A., Poston, K. L., Mormino, E. C., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00590-4 · Cited by 80 · see citing works
Bejanin, A., Iulita, M. F., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., Fernandez, S., Altuna, M., Pegueroles, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1893 · Cited by 76 · see citing works
Self-citationApolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid
Heinsinger, N. M., Gachechiladze, M. A., & Rebeck, G. W. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw067 · Cited by 74 · see citing works
Relationship between frailty and Alzheimer's disease biomarkers: a scoping review
Wallace, L., Theou, O., Rockwood, K., & Andrew, M. K. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.05.002 · Cited by 72 · see citing works
- Authors
- Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I. S., Arnold, S. E., Baldeiras, I., Barthel, H., van Berckel, B. N. M., Bibeau, K., Blennow, K., Brooks, D. J., van Buchem, M. A., Camus, V., Cavedo, E., Chen, K., Chetelat, G., Cohen, A. D., Drzezga, A., Engelborghs, S., Fagan, A. M., Fladby, T., Fleisher, A. S., van der Flier, W. M., Ford, L., Förster, S., Fortea, J., Foskett, N., Frederiksen, K. S., Freund-Levi, Y., Frisoni, G. B., Froelich, L., Gabryelewicz, T., Gill, K. D., Gkatzima, O., Gómez-Tortosa, E., Gordon, M. F., Grimmer, T., Hampel, H., Hausner, L., Hellwig, S., Herukka, S.-K., Hildebrandt, H., Ishihara, L., Ivanoiu, A., Jagust, W. J., Johannsen, P., Kandimalla, R., Kapaki, E., Klimkowicz-Mrowiec, A., Klunk, W. E., Köhler, S., Koglin, N., Kornhuber, J., Kramberger, M. G., Van Laere, K., Landau, S. M., Lee, D. Y., de Leon, M., Lisetti, V., Lleó, A., Madsen, K., Maier, W., Marcusson, J., Mattsson, N., de Mendonça, A., Meulenbroek, O., Meyer, P. T., Mintun, M. A., Mok, V., Molinuevo, J. L., Møllergård, H. M., Morris, J. C., Mroczko, B., Van der Mussele, S., Na, D. L., Newberg, A., Nordberg, A., Nordlund, A., Novak, G. P., Paraskevas, G. P., Parnetti, L., Perera, G., Peters, O., Popp, J., Prabhakar, S., Rabinovici, G. D., Ramakers, I. H. G. B., Rami, L., Resende de Oliveira, C., Rinne, J. O., Rodrigue, K. M., Rodríguez-Rodríguez, E., Roe, C. M., Rot, U., Rowe, C. C., Rüther, E., Sabri, O., Sanchez-Juan, P., Santana, I., Sarazin, M., Schröder, J., Schütte, C., Seo, S. W., Soetewey, F., Soininen, H., Spiru, L., Struyfs, H., Teunissen, C. E., Tsolaki, M., Vandenberghe, R., Verbeek, M. M., Villemagne, V. L., Vos, S. J. B., van Waalwijk van Doorn, L. J. C., Waldemar, G., Wallin, A., Wallin, Å. K., Wiltfang, J., Wolk, D. A., Zboch, M., & Zetterberg, H.
- Affiliations
- Maastricht University (NL)
- Amsterdam Neuroscience (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Stavanger University Hospital (NO)
- Hospital de Sant Pau (ES)
- Roche (United Kingdom) (GB)
- Akershus University Hospital (NO)
- University of Pennsylvania (US)
- Unidade Local de Saúde de Coimbra (PT)
- Leipzig University (DE)
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands
- GlaxoSmithKline (United States) (US)
- University of Gothenburg (SE)
- Imperial College London (GB)
- Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
- Université de Tours (FR)
- Sorbonne Université (FR)
- Banner Alzheimer’s Institute (US)
- Institut National de la Santé et de la Recherche Médicale (Inserm), U1077, Caen, France
- University of Pittsburgh (US)
- University of Cologne (DE)
- University of Antwerp (BE)
- Washington University in St. Louis (US)
- University of California San Diego (US)
- Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands6Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands
- Janssen Research and Development, Titusville, New Jersey
- Technical University of Munich (DE)
- University of Copenhagen (DK)
- Department of Geriatrics, Institution of NVS, Section of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden
- University of Geneva (CH)
- Heidelberg University (DE)
- Mossakowski Medical Research Institute, Polish Academy of Sciences (PL)
- Post Graduate Institute of Medical Education and Research (IN)
- Aristotle University of Thessaloniki (GR)
- Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain
- Boehringer Ingelheim (United States) (US)
- TUM Klinikum (DE)
- Inserm (FR)
- University Medical Center Freiburg (DE)
- University of Eastern Finland (FI)
- Center for Neurology, Hospital of Bremen-Ost, Bremen, Germany
- GlaxoSmithKline (United Kingdom) (GB)
- Cliniques Universitaires Saint-Luc (BE)
- University of California, Berkeley (US)
- Rigshospitalet (DK)
- Emory University (US)
- National and Kapodistrian University of Athens (GR)
- Jagiellonian University College of Medicine, Krakow, Poland
- Piramal (Germany) (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Ljubljana University Medical Centre (SI)
- Department of Imaging and Pathology, Catholic University Leuven, Leuven, Belgium
- Seoul National University (KR)
- School of Medicine, Center for Brain Health, New York University, New York
- University of Perugia (IT)
- Copenhagen University Hospital (DK)
- University of Bonn (DE)
- Linköping University (SE)
- Lund University (SE)
- Institute of Molecular Medicine and Faculty of Medicine, University of Lisbon, Portugal
- Radboud University Medical Center (NL)
- Avid Radiopharmaceuticals (United States) (US)
- Chinese University of Hong Kong (HK)
- Alzheimer’s Disease and Other Cognitive Disorders Unit, IDIBAPS, Clinic University Hospital, Barcelona, Spain
- Medical University of Białystok (PL)
- Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium
- Samsung Medical Center (KR)
- Thomas Jefferson University (US)
- Karolinska University Hospital (SE)
- King's College London (GB)
- German Center for Neurodegenerative Diseases (DE)
- Centre Hospitalier Universitaire Vaudois (CH)
- University of California, San Francisco (US)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Center for Neuroscience and Cell Biology, Faculty of Medicine, Hospital Center University of Coimbra, Portugal
- University of Turku (FI)
- The University of Texas at Dallas (US)
- Neurology Service, Universitary Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain
- Center for Cognitive Impairments, University Medical Centre Ljubljana, Ljubljana, Slovenia
- Austin Hospital (AU)
- Universitätsmedizin Göttingen (DE)
- Centre Hospitalier Sainte-Anne (FR)
- Carol Davila University of Medicine and Pharmacy (RO)
- KU Leuven (BE)
- Departments of Neurology and Laboratory Medicine, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands
- Wroclaw Medical University (PL)
- National Hospital for Neurology and Neurosurgery (GB)
- ORCID
- Jansen, Willemijn J.
- Ossenkoppele, Rik
- Tijms, Betty M.
- Scheltens, Philip
- Verhey, Frans R. J.
- Visser, Pieter Jelle
- Aarsland, Dag
- Alcolea, Daniel
- Alexander, Myriam
- Almdahl, Ina S.
- Arnold, Steven E.
- Baldeiras, Inês
- Barthel, Henryk
- Bibeau, Kristen
- Blennow, Kaj
- Brooks, David J.
- Camus, Vincent
- Cavedo, Enrica
- Chen, Kewei
- Cohen, Ann D.
- Drzezga, Alexander
- Engelborghs, Sebastiaan
- Fagan, Anne M.
- Fladby, Tormod
- Fleisher, Adam S.
- Ford, Lisa
- Förster, Stefan
- Fortea, Juan
- Frederiksen, Kristian S.
- Frisoni, Giovanni B.
- Froelich, Lutz
- Gkatzima, Olymbia
- Gordon, Mark Forrest
- Grimmer, Timo
- Hampel, Harald
- Hausner, Lucrezia
- Hellwig, Sabine
- Herukka, Sanna-Kaisa
- Hildebrandt, Helmut
- Jagust, William J.
- Johannsen, Peter
- Kandimalla, Ramesh
- Klunk, William E.
- Köhler, Sebastian
- Koglin, Norman
- Kornhuber, Johannes
- Kramberger, Milica G.
- Landau, Susan M.
- Lee, Dong Young
- Lleó, Alberto
- Madsen, Karine
- Maier, Wolfgang
- Marcusson, Jan
- Mattsson, Niklas
- Meyer, Philipp T.
- Mok, Vincent
- Morris, John C.
- Mroczko, Barbara
- Na, Duk L.
- Newberg, Andrew
- Nordberg, Agneta
- Novak, Gerald P.
- Paraskevas, George P.
- Parnetti, Lucilla
- Perera, Gayan
- Peters, Oliver
- Popp, Julius
- Rabinovici, Gil D.
- Ramakers, Inez H. G. B.
- Rami, Lorena
- Rinne, Juha O.
- Rodrigue, Karen M.
- Roe, Catherine M.
- Rowe, Christopher C.
- Sabri, Osama
- Santana, Isabel
- Sarazin, Marie
- Schröder, Johannes
- Seo, Sang W.
- Soininen, Hilkka
- Spiru, Luiza
- Teunissen, Charlotte E.
- Tsolaki, Magda
- Vandenberghe, Rik
- Verbeek, Marcel M.
- Villemagne, Victor L.
- Vos, Stephanie J. B.
- Waldemar, Gunhild
- Wallin, Anders
- Wiltfang, Jens
- Wolk, David A.
- Zboch, Marzena
- Zetterberg, Henrik
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-05-19
- Volume
- 313
- Issue
- 19
- Pages
- 1924
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4486209
- OpenAlex
- W2168357345
- Cited by
- 1,610
- References
- 51
- Citations by year
- 2026: 118 · 2025: 144 · 2024: 168 · 2023: 140 · 2022: 151 · 2021: 174 · 2020: 184 · 2019: 142 · 2018: 135 · 2017: 117 · 2016: 92 · 2015: 43 · 2014: 1
- FWCI
- 104.60
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- VU Research Portal (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Digital Access to Libraries (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- mediaTUM (Technical University of Munich) (submittedVersion)
- GRO (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Science Foundation (P01AG003991,, P50AG005681, P01 AG026276, FP7/2007-2013, P50 AG005133, U01 AG024904)
- U.S. Department of Defense (U01 AG024904, W81XWH, W81XWH-12-2-, W81XWH1220012, AG024904)
- Foundation for the National Institutes of Health (P01AG026276, W81XWH-12-2-0012, U01AG024904, AG024904, P01AG003991)
- Alzheimer's Association (P01 AG003991, P50 AG005681, U01 AG024904, W81XWH-12-2-0012)
- Bristol-Myers Squibb (U01 AG024904, AG024904, W81XWH-12-2-0012)
- Eli Lilly and Company (U01 AG024904, AG024904, W81XWH-12-2-0012)
- Pfizer (AG024904, W81XWH-12-2-0012, 115372, U01 AG024904)
- AstraZeneca
- GlaxoSmithKline (P01AG026276)
- Biogen (W81XWH-12-2-0012, U01 AG024904, AG024904)
- University of Southern California (P01 AG003991, W81XWH-12-2-0012, P01 AG026276, U01 AG024904)
- University of Pennsylvania
- Emory University
- F. Hoffmann-La Roche (W81XWH-12-2-0012, AG024904, U01 AG024904)
- Medpace (U01 AG024904)
- Meso Scale Diagnostics (U01 AG024904, AG024904, W81XWH-12-2-0012)
- Synarc (U01 AG024904)
- Alzheimer's Disease Neuroimaging Initiative (P01AG026276, W81XWH-12-2–0012, U01AG024904, AG024904, W81XWH-12-2-)
- BioClinica (U01 AG024904, W81XWH-12-2-0012, AG024904)
- Itä-Suomen Yliopisto
- National Research Centre
- University of Pittsburgh (P50 AG005133)
- Sundhed og Sygdom, Det Frie Forskningsråd
- Thomas Jefferson University
- Science and Industry Endowment Fund
- Northern California Institute for Research and Education (U01 AG024904, W81XWH-12-2-0012)
- EU Joint Programme – Neurodegenerative Disease Research
- European Federation of Pharmaceutical Industries and Associations (FP7/20072013, ANR-10-IAIHU-06, 115372)
- Postgraduate Institute of Medical Education and Research, Chandigarh
- Lui Che Woo Institute of Innovative Medicine
- York University
- Imperial College London
- European Commission (37670, U01 AG024904, 601055, 2007–2013, FP7 2007-2013, LSHB-CT-2005-512146, FP7/2007, W81XWH-12-2-0012, QLRT-2001-2455, 115372)
- Bayer HealthCare
- Commonwealth Scientific and Industrial Research Organisation
- Indian Council of Medical Research
- Deutsche Forschungsgemeinschaft (HE 4560/1-2, DR 445/3-1, 115372, FP7/2007–2013, DR 445/4-1)
- Universität Heidelberg
- Agence Nationale de la Recherche (ANR-10-IAIHU06, 10-IAIHU-06, ANR-10)
- Institut National de la Santé et de la Recherche Médicale (ANR-10-IAIHU-06, INSERM U930)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (FP7/2007-2013, 37670)
- Universiteit Leiden
- Edith Cowan University
- ZonMw
- Universiteit van Amsterdam
- Radboud Universiteit
- Vrije Universiteit Amsterdam (FP7/2007-2013)
- AXA Research Fund (ANR-10-IAIHU-06)
- Academy of Finland (W81XWH-12-2-0012, 115372, U01 AG024904)
- Bundesministerium für Bildung und Forschung (01GI1007A, 01GI0420)
- Seoul National University (FP7/2007-2013)
- Sungkyunkwan University
- Belgian Federal Science Policy Office
- Gentofte Hospital
- Dementia Collaborative Research Centres, Australia
- Fonds Wetenschappelijk Onderzoek
- Ministero della Salute
- Lunds Universitet
- Lundbeckfonden
- Eisai (W81XWH-12-2-0012, U01 AG024904, AG024904)
- KU Leuven
- Karolinska Institutet
- Kuopion Yliopistollinen Sairaala
- Chinese University of Hong Kong
- Leids Universitair Medisch Centrum
- Rigshospitalet
- National and Kapodistrian University of Athens
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- Turun Yliopisto
- Technische Universität München
- Universidade de Coimbra
- Université Pierre et Marie Curie (FP7/2007-2013)
- Göteborgs Universitet
- Universidade de Lisboa
- Center for Translational Molecular Medicine (02N-101)
- Radboud Universitair Medisch Centrum
- Université de Genève
- Aristotle University of Thessaloniki
- Universiteit Antwerpen (FP7/2007-2013)
- Universitatea de Medicină şi Farmacie "Carol Davila" Bucureşti
- Universität zu Köln
- Rheinische Friedrich-Wilhelms-Universität Bonn
- Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu
- Università degli Studi di Perugia (ANR-10-IAIHU-06)
- Innovative Medicines Initiative (#115372, FP7/2007‐2013)
- Servier (AG024904, W81XWH-12-2-0012, U01 AG024904)
- Turun Yliopistollinen Keskussairaala
- Vlaamse regering
- Merz Pharmaceuticals
- H. Lundbeck A/S (U01 AG024904, AG024904, W81XWH-12-2-0012)
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
- IXICO (AG024904, W81XWH-12-2-0012, U01 AG024904)
- Région Normandie
- Instituto de Investigación Marqués de Valdecilla
- Sorbonne Université
- Fondation pour la Recherche sur Alzheimer (ANR-10-IAIHU-06)
- National Institutes of Health (3u01ag024904-10s2, FP7/2007-2013, W81XWH, W81XWH-12-2-0012, U01-AG024904, AG005133, R01 AG12101, AG008051, AG024904, AG005681, AG12101, AG025204, AG003991, AG026276, AG025516, ANR-10-IAIHU-06)
- Genentech (W81XWH-12-2-0012, AG024904, U01 AG024904)
- Samsung
- University of California, San Diego (P50 AG005133)
- Avid Radiopharmaceuticals
- Canadian Institutes of Health Research (U01 AG024904, W81XWH-12-2-0012)
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis (P01AG003991)
- Medical Research Council (U01 AG024904)
- Menzies Centre for Australian Studies, King's College London, University of London
- National Health and Medical Research Council
- Instituto de Salud Carlos III (PI11/, PI13/01532)
- Sahlgrenska Akademin
- European Regional Development Fund (FP7/2007‐2013, 2007 – 2013, 20/21)
- Krajowy Naukowy Osrodek Wiodacy
- National Institute on Aging (U01-AG-024904, AG008051, R01AG13616, AG022374, W81XWH-12-2–0012, P01AG025204, AG-005133, RF1AG025516, P50AG005133, AG 024904, R01AG022374, P30AG010124, AG 12101, AG003991, R01AG012101, P30AG008051, AG026276, P50AG005681, AG025204, P01AG003991, R01-AG-12101, U19AG032438, U19AG010483, R37AG025516, R01AG013616, AG005681, P01AG026276, R01AG025516, AG 13616)
- National Institute of Biomedical Imaging and Bioengineering (W81XWH-12-2-0012, U01 AG024904, AG024904)
- Janssen Research and Development
- Janssen Pharmaceuticals
- Cilag
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
- Keywords
- cerebral amyloid-beta, Alzheimer's disease, mild cognitive impairment, subjective cognitive impairment, normal cognition, APOE ε4 carriers, APOE genotype, positron emission tomography, cerebrospinal fluid biomarkers, sex differences, dementia prevention
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Brain, Cerebrospinal Fluid, Dementia, Female, Genotype, Humans, Male, Middle Aged, Risk Factors, Biomarkers, Prevalence, Amyloid beta-Peptides, Positron-Emission Tomography, Apolipoprotein E4, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
